<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671186</url>
  </required_header>
  <id_info>
    <org_study_id>20-0198</org_study_id>
    <nct_id>NCT04671186</nct_id>
  </id_info>
  <brief_title>Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan</brief_title>
  <official_title>Role of Probiotics in Treatment of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Patients by Assessing With Fibroscan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the role of probiotics in the treatment of pediatric&#xD;
      NAFLD by evaluating for steatosis and fibrosis with a Fibroscan machine. This will be done by&#xD;
      performing a fibroscan during each visit and comparing patients' ALT at various intervals.&#xD;
      This is an important study as current pediatric guidelines only recommend lifestyle&#xD;
      modifications for the treatment of NAFLD and the use of ALT and sonogram to assess&#xD;
      improvement as standard of care. Investigators hypothesized that treatment with a probiotic&#xD;
      will demonstrate an improvement in NAFLD as assessed by a fibroscan of liver which is good&#xD;
      for the monitoring of steatosis and fibrosis. Additionally, analysis of fecal microbiome&#xD;
      results may offer insight into targeted therapy in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal/objective of this study is to evaluate the role of probiotics in the treatment of&#xD;
      NAFLD by assessing with fibroscan in both newly diagnosed and known pediatric patients with&#xD;
      NAFLD. This will be done by performing a fibroscan during each visit and comparing patient&#xD;
      ALT and fecal microbiome at various intervals.&#xD;
&#xD;
      The primary endpoint is to assess the effect of probiotic treatment in liver steatosis and&#xD;
      fibrosis by assessing with fibroscan using CAP score and TE staging. The higher the CAP score&#xD;
      (S1, S2, S3) so worse the steatosis. TE staging (F0-F4), higher the staging indicates&#xD;
      worsening of fibrosis.&#xD;
&#xD;
      Secondary endpoints include:&#xD;
&#xD;
        -  The rate of decline of ALT over 3 month time interval and through whole study starting&#xD;
           at initial diagnosis.&#xD;
&#xD;
        -  The rate of decrease in hepatic steatosis and BMI&#xD;
&#xD;
      This study will target pediatric patients with NAFLD. Participants will be new and previously&#xD;
      diagnosed NAFLD patients between the ages of 5 years and 18 years.&#xD;
&#xD;
      This is single center study. Investigators will enroll patients from The Division of&#xD;
      Pediatric Gastroenterology, Liver Disease and Nutrition.&#xD;
&#xD;
      Participants will be blindly randomized into one of two groups: probiotic or placebo.&#xD;
&#xD;
      Investigators expect the study to run for 1 year from 09/15/2020 to 09/14/2021. Investigators&#xD;
      will enroll patients over a 6 month period. After randomization into two separate groups&#xD;
      (probiotic vs placebo), Investigators plan to collect data for the subsequent 6 months&#xD;
      following enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">September 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 6, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be blindly randomized at Visit 1 into one of two groups (probiotic or placebo). Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) and the other group receive placebo oral capsule daily throughout the study. All participants in either group will undergo: Life style modification as per NASPGHAN NAFLD guidelines. Fibroscan assessing CAP and TE score once every 3 month until the end of study. Monitoring ALT every 3 months until end of study as per standard of care guidelines.Collection of stool sample to be sent for microbiome analysis at the time of diagnosis, 3 months and 6 months (end of the study). Secondary variables collected, Age, Gender, Race, BMI, Fibroscan probe.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants will be blindly randomized at baseline (Visit 1) into one of two groups: probiotic or placebo. Investigators are to be blinded as well</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The role of probiotics in the treatment of pediatric NAFLD by evaluating for steatosis with a Fibroscan machine.</measure>
    <time_frame>One year</time_frame>
    <description>The primary endpoint/outcome assesses the effect of probiotic treatment in liver steatosis by assessing with fibroscan using CAP score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The role of probiotics in the treatment of pediatric NAFLD by evaluating for fibrosis with a Fibroscan machine.</measure>
    <time_frame>One year</time_frame>
    <description>The primary endpoint/outcome assesses the effect of probiotic treatment in liver fibrosis by assessing with fibroscan using TE staging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of decline in ALT.</measure>
    <time_frame>One year</time_frame>
    <description>The rate of decline of ALT over 3 month time interval and through whole study starting at initial diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal microbiome</measure>
    <time_frame>One year</time_frame>
    <description>Compare changes in stool microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in BMI</measure>
    <time_frame>One year</time_frame>
    <description>The rate of change in hepatic steatosis with change in BMI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Probiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic group will receive Lactobacillus rhamnosus strain GG one capsule oral daily (10 billion CFU/day) throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group is to receive placebo oral capsule daily throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Culturelle (Lactobacillus rhamnosus strain GG)</intervention_name>
    <description>Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily</description>
    <arm_group_label>Probiotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo group will take 1 capsule of placebo orally once daily</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  This study will target pediatric patients with NAFLD. Participants will be new and&#xD;
             previously diagnosed NAFLD patients between the ages of 5 years and 18 years.&#xD;
             Diagnosis must be made by elevated serum ALT (two times above the sex specific upper&#xD;
             limit of normal) and a sonogram consistent with steatosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria for both groups&#xD;
&#xD;
               -  Concomitant underlying liver disease such as but not limited to autoimmune&#xD;
                  hepatitis&#xD;
&#xD;
               -  Concomitant infectious hepatitis&#xD;
&#xD;
               -  Medication use of steroids, methotrexate, metformin, and therapeutic dose of Vit.&#xD;
                  E&#xD;
&#xD;
               -  Recent antibiotic use in last 4 weeks&#xD;
&#xD;
               -  Clinically significant weight loss (at least 5% reduction in weight from baseline&#xD;
                  level [18]) on follow up NAFLD patients who were on life style modification&#xD;
                  intervention&#xD;
&#xD;
               -  Cirrhosis (Fibroscan score â‰¥14.0)&gt;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shari Sheflin-Findling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cohen Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kanya Ahuja, MBBS</last_name>
    <phone>516-4723650</phone>
    <email>kahuja3@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shari Sheflin-Findling, DO</last_name>
    <phone>516-4723650</phone>
    <email>SSheflin@northwell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kanya Ahuja, MBBS</last_name>
      <phone>516-472-3650</phone>
      <email>kahuja3@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shari Sheflin-Findling, DO</last_name>
      <phone>516-4723650</phone>
      <email>SSheflin@northwell.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015 Mar;148(3):547-55. doi: 10.1053/j.gastro.2014.11.039. Epub 2014 Nov 25.</citation>
    <PMID>25461851</PMID>
  </reference>
  <reference>
    <citation>Alisi A, Manco M, Vania A, Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr. 2009 Oct;155(4):469-74. doi: 10.1016/j.jpeds.2009.06.014. Review.</citation>
    <PMID>19772998</PMID>
  </reference>
  <reference>
    <citation>Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Nov 14;20(42):15518-31. doi: 10.3748/wjg.v20.i42.15518. Review.</citation>
    <PMID>25400436</PMID>
  </reference>
  <reference>
    <citation>Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334. doi: 10.1097/MPG.0000000000001482.</citation>
    <PMID>28107283</PMID>
  </reference>
  <reference>
    <citation>Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric PatientsAuthor links open overlay panel NiravK.DesaiMD1,SarahHarneyBA1,RoshanRazaMD1,AlyaaAlIbraheemiMD2, NickShillingfordMD2, Paul D.MitchellMS3, Maureen M.JonasMD1</citation>
  </reference>
  <reference>
    <citation>Schwimmer JB, Newton KP, Awai HI, Choi LJ, Garcia MA, Ellis LL, Vanderwall K, Fontanesi J. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 Nov;38(10):1267-77. doi: 10.1111/apt.12518. Epub 2013 Oct 1.</citation>
    <PMID>24117728</PMID>
  </reference>
  <reference>
    <citation>Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol. 2019 May;13(5):447-461. doi: 10.1080/17474124.2019.1595589. Epub 2019 Apr 4. Review.</citation>
    <PMID>30875479</PMID>
  </reference>
  <reference>
    <citation>Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25. doi: 10.1038/nrgastro.2016.85. Epub 2016 Jun 8. Review.</citation>
    <PMID>27273168</PMID>
  </reference>
  <reference>
    <citation>Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int. 2015;2015:979515. doi: 10.1155/2015/979515. Epub 2015 May 19. Review.</citation>
    <PMID>26090468</PMID>
  </reference>
  <reference>
    <citation>Ley RE, BÃ¤ckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5. Epub 2005 Jul 20.</citation>
    <PMID>16033867</PMID>
  </reference>
  <reference>
    <citation>Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006 Feb 24;124(4):837-48. Review.</citation>
    <PMID>16497592</PMID>
  </reference>
  <reference>
    <citation>Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.</citation>
    <PMID>22297845</PMID>
  </reference>
  <reference>
    <citation>Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.</citation>
    <PMID>23401313</PMID>
  </reference>
  <reference>
    <citation>Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, GÃ©rard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12):1787-94. doi: 10.1136/gutjnl-2012-303816. Epub 2012 Nov 29.</citation>
    <PMID>23197411</PMID>
  </reference>
  <reference>
    <citation>Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014 Jun;39(11):1276-85. doi: 10.1111/apt.12758. Epub 2014 Apr 16.</citation>
    <PMID>24738701</PMID>
  </reference>
  <reference>
    <citation>Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011 Jun;52(6):740-3. doi: 10.1097/MPG.0b013e31821f9b85.</citation>
    <PMID>21505361</PMID>
  </reference>
  <reference>
    <citation>Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015 Mar 27;7(3):559-65. doi: 10.4254/wjh.v7.i3.559. Review.</citation>
    <PMID>25848479</PMID>
  </reference>
  <reference>
    <citation>Effects of Clinically Significant Weight Loss with Exercise Training on Insulin Resistance and Cardiometabolic Adaptations. Damon L. Swift, Ph.D.,1,2 Neil M. Johannsen, Ph.D.,3 Carl J. Lavie, M.D.,4 Conrad P. Earnest, Ph.D.,5 Steven N. Blair, P.E.D.,6 and Timothy S. Church, M.D., Ph.D.7 2005;102(31):11070-11075. doi:10.1073/pnas.0504978102</citation>
  </reference>
  <reference>
    <citation>Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2010 Sep;105(9):2093-102. doi: 10.1038/ajg.2010.152. Epub 2010 Apr 6.</citation>
    <PMID>20372110</PMID>
  </reference>
  <reference>
    <citation>Fusillo S, Rudolph B. Nonalcoholic fatty liver disease. Pediatr Rev. 2015 May;36(5):198-205; quiz 206. doi: 10.1542/pir.36-5-198. Review.</citation>
    <PMID>25934909</PMID>
  </reference>
  <reference>
    <citation>Awai HI, Newton KP, Sirlin CB, Behling C, Schwimmer JB. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol. 2014 May;12(5):765-73. doi: 10.1016/j.cgh.2013.09.050. Epub 2013 Sep 30. Review.</citation>
    <PMID>24090729</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04671186/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04671186/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

